ClinicalTrials.gg
Active, not recruitingNCT07386938Updated Jul 14, 2026

A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer

A Phase 3 interventional study of RPH-051 and Docetaxel in Locally Advanced Breast Cancer and Metastatic Breast Cancer, sponsored by R-Pharm. Active, not recruiting at 45 sites in Russia. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by R-Pharm · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Aug 2024, registered Jan 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
246
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.

Planned enrollment
55th of 248
246 · median 68
Started
2024
with 6 others
Phase 3
51 of 264
5 open now
Primary completion
2025-10
later than 8 of 25 live
Registered
260th of 264
by date

Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 55th largest by planned enrollment of the 248 interventional ones that give a count, is one of 7 that started in 2024, is one of 51 in phase 3, reaches primary completion later than 8 of the 25 other live ones, and was the 260th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies testing docetaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

The main purpose of this study is to prove non-inferiority, as well as to demonstrate the comparability of safety and immunogenicity of RPH-051 and Perjeta® in combination with trastuzumab and docetaxel as the 1st line therapy for patients with HER2-positive breast cancer (BC). Secondary Purposes are to evaluate the pharmacokinetics of RPH-051 in comparison with Perjeta® after a single-dose and repeated intravenous administration

Read the detailed description

This study is an international, multicenter, double-blind, randomized, comparative, phase III study

Pertuzumab therapy combined with trastuzumab and docetaxel (6 cycles) within this study will last up to 2 years or until the disease progression/development of unacceptable toxicity (whichever comes first)

A subgroup of participants (at least 60 participants, approximately 30 participants in each treatment group) is planned to be included for pharmacokinetic evaluation

The study will include the following periods:

  1. Screening period: days -27 to 0 (up to 1 administration of the study therapy)

    If a biopsy of the tumor material to study the HER2 status is required, the screening period can be extended to 42 days

  2. Main period: days 1 to 126

    Eligible patients will be randomized at the ratio of 1:1 to one of the two study arms: RPH-051 + trastuzumab + docetaxel or Perjeta® + trastuzumab + docetaxel. On Day 1 (and Day 43 in the PK-subgroup) or the day before, the patients may be hospitalized and will remain in the clinic for up to 24 hours after administration of the first dose of the study drug

    Within the Main period of the Study, the patients will receive pertuzumab (RPH-051 or Perjeta® drug products) combined with trastuzumab and docetaxel according to the following scheme: pertuzumab 420 mg (loading dose 840 mg in the 1st cycle) IV on Day 1 once every 3 weeks + trastuzumab 6 mg/kg (loading dose 8 mg/kg in the 1st cycle) IV on Day 1 once every 3 weeks + docetaxel 75 mg/m2 IV on Day 1 once every 3 weeks, 6 cycles

    In case of significant adverse events (AEs), treatment could be delayed for at least 3 weeks

    The therapy within the Main period will continue until (whichever comes first):

    • 18 weeks (6 cycles)
    • disease progression (according to RECIST 1.1 / clinical progression criteria)
    • development of unacceptable toxicity.
  3. Period of extended therapy: days 127 to 365

    During the period of extended therapy, all patients will receive RPH-051 therapy in combination with trastuzumab, including those who received Perjeta® during the Main period. Therapy will be carried out according to the scheme: pertuzumab 420 mg IV once every 3 weeks + trastuzumab 6 mg/kg IV once every 3 weeks

    In case of significant adverse events (AEs), treatment could be delayed for at least 3 weeks

    The therapy during the Period of extended therapy will continue until (whichever comes first):

    • up to 1 year
    • until disease progression (according to RECIST 1.1/clinical progression criteria)
    • development of unacceptable toxicity

    If, after a year of therapy, the patient who achieved control of the disease, she goes into the follow-up care period

  4. Follow-up care period: days 366 to 730

    During the follow-up care period, all patients will continue RPH-051 therapy in combination with trastuzumab, including those who received Perjeta® during the Main study period. The therapy will be carried out according to the previous scheme: pertuzumab 420 mg IV once every 3 weeks + trastuzumab 6 mg/kg IV once every 3 weeks

    In case of significant adverse events (AEs), treatment could be delayed for at least 3 weeks

    The therapy during the follow-up care period will continue until (whichever comes first):

    • up to 2 years
    • until disease progression (according to RECIST 1.1/clinical progression criteria)
    • development of unacceptable toxicity
    • the patient's refusal to continue therapy
  5. Follow-up period (follow-up/FU)

One follow-up visit (FU-visit) will be scheduled 28 ± 3 days after the last administration

For the patients who early withdraw due to progression of the disease, FU visits will take place once every 6 weeks (counting from the date of the early termination visit) until Day 365 of the study or until lethal outcome

If a patient discontinues the therapy within the main period and the extended therapy period for a reason other than progression of the disease, and other treatment regimen is not prescribed to her, further FU visits will be held in the form of evaluation of the tumor response by CT/MRI once every 6 weeks until Day 126 and then once every 12 weeks until Day 365 of the study or until the disease progression/prescription of other therapy, whichever comes first. Upon the disease progression/prescription of another therapy, the patient follow-up will continue in the form of telephone contacts once every 6 weeks until Study Day 365 or until lethal outcome

If a patient discontinues the therapy with the study drug within the follow-up care period for any reason, FU visits will take place once every 6 weeks (counting from the date of the early termination visit) in the form of telephone contacts until Day 730 of the study or until lethal outcome

03

Conditions studied

  • Locally Advanced Breast Cancer
  • Metastatic Breast Cancer

Browse trials for

Keywords

  • Locally advanced breast cancer
  • Metastatic breast cancer
  • RPH-051
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

The patients must meet all the following inclusion criteria:

  1. Voluntarily signed and dated Form (ICF) of the patient agreed to take part in this Study
  2. verified (documented results of respective examinations available) or locally recurrent unresectable breast adenocarcinoma (in case the results of previous examinations are not available, the diagnosis will be verified in the central laboratory during screening upon receipt and evaluation of the results before randomization)
  3. Patients with metastatic or locally recurrent unresectable breast cancer (BC) who have indications for the therapy
  4. -positive tumor status, defined as 3+ points according to the results of immunohistochemical examination (IHC) and/or detected amplification of HER2 according to the results of fluorescence in situ hybridization (as defined by a ratio ≥ 2,0), evaluated using a validated test. The HER2 status analysis is carried out in the invasive component of a sample of tumor tissue during screening in the central laboratory. The results must be obtained before making a decision on randomization of the patient. For analysis, it is required to provide the blocks no more than 1 year old, obtained from the treatment-naive lesions, or a biopsy is performed as a part of screening
  5. status 0-1.
  6. (LVEF) ≥ 55 % during the screening.
  7. Presence of at least one in accordance with the 1.1 criteria (if the patient's only measurable lesion is a bone one, she cannot be enrolled in the study).
  8. Absence or resolution of the previous therapy toxic effects or negative consequences of surgeries of up to ≤ 1 gr. according to 5.0, with the exception of chronic/irreversible adverse events that do not affect the safety parameters of the study therapy (for example, alopecia)
  9. of at least 18 weeks from the date of randomization (in the opinion of the Investigator)
  10. Consent of a patient with preserved to abstain from heterosexual contact or use reliable methods of , starting from the time the Informed Consent Form is signed, throughout the entire period of treatment within the study and 7 months after receiving the last infusion of pertuzumab and trastuzumab. Female patients are considered to be incapable of childbearing if the final cessation of menstruation is confirmed retrospectively after 12 months of natural amenorrhea, i.e. amenorrhea with an appropriate clinical status, for example, a suitable age

Additional criteria for inclusion in PK subgroups

  1. Availability of the signed Informed Consent Form to participate in the pharmacokinetic study
  2. Body weight in the range of 40-100 kg at the time the ICF is signed
  3. Patient's capability, in the justified opinion of the Investigator, to participate in the pharmacokinetic study and possibility to take the required number of blood samples

The patients cannot be included in the study if any of the following exclusion criteria is met:

  1. Previous antitumor therapy for metastatic or locally recurrent unresectable BC (/adjuvant therapy with trastuzumab and one hormone therapy regimen for the metastatic process are allowed)
  2. Previous pertuzumab therapy
  3. The period without the signs of disease from the completion of the systemic neoadjuvant or adjuvant BC therapy (except hormonal therapy) to the established diagnosis of the metastatic process or recurrence in \< 12 months
  4. The period from completion of the systemic neoadjuvant or adjuvant BC therapy with trastuzumab and docetaxel to the start of the systemic therapy for metastatic or locally recurrent unresectable process with a combination of pertuzumab + trastuzumab + docetaxel is \< 12 months
  5. Sustained hematological toxicity (, leukocytes, neutrophils, ) ≥ grade 2, resulting from the previous adjuvant therapy
  6. Peripheral neuropathy ≥ grade 3 at the time the ICF is signed
  7. Other oncological pathology that is progressing or requires antitumor therapy (including hormonal therapy) within 5 years before signing the ICF, except radically removed cervical carcinoma in situ or radically removed basal cell/squamous cell skin carcinoma
  8. Central nervous system metastases that are progressive or accompanied by clinical symptoms (for example, cerebral edema, compression of the spinal cord), or require the application of glucocorticosteroids (GCS) at a dose equivalent to daily intake of prednisolone > 10 mg (or dexamethasone > 1.5 mg), and/or anticonvulsants. Patients with can be included in the study if they receive adequate therapy (surgery or radiotherapy) and are stabilized according to the imaging studies data for at least 4 weeks before the expected date of randomization into the study. Patients with CNS metastases detected for the first time as a part of screening, which are not accompanied by neurological symptoms and do not require any therapy, can be included in the study
  9. History of treatment with cumulative doses of anthracyclines
  10. Patients with severe concomitant diseases, with life-threatening acute complications of the underlying disease
  11. Concomitant diseases that are ongoing at the time of the screening examination and that increase the patient's risk of developing adverse events during the application of study therapy:

    • stable effort angina, Functional Class III-IV, unstable angina
    • history of myocardial infarction or stroke occurred less than 6 months before signing of the IC form
    • rhythm disturbances (patients with asymptomatic atrial fibrillation can be included in the study provided the ventricular rhythm is controlled)
    • chronic cardiac failure, Class III-IV according to (NYHA) classification
    • uncontrolled arterial hypertension (systolic blood pressure over 150 mmHg or diastolic blood pressure over 90 mmHg during antihypertensive therapy)
    • decrease in LVEF to \< 50 % in the medical history during or after the previous neoadjuvant or adjuvant trastuzumab therapy
    • severe respiratory failure, as well as dyspnea at rest due to complications of advanced cancer or other diseases requiring continuous oxygen therapy
    • current severe uncontrolled systemic disease
    • any other concomitant disease or condition that significantly increases the risk of developing an AE during the study, in the opinion of the Investigator
  12. Major surgery or significant injury less than 28 days before, radiation therapy (other than palliative) less than 14 days before the IC form is signed, or a planned major surgery during treatment within this study
  13. Non-healing wounds, ulcers at the time the ICF is signed
  14. Hematological disorders (in case any of the following):

    • neutrophils \< 1.5 x 109/L
    • platelets \<100 x 109/L
    • hemoglobin \< 90 g/L
  15. Renal dysfunction:

    • creatinine > 1.5 × or \< 45 mL/min (calculated using CKD-EPI formula)
  16. Liver dysfunction (in case any of the following):

    • ≥ 1.5 × ULN (except for patients with Gilbert's syndrome, whose total bilirubin values should not exceed 50 µmol/L)
    • or ALT ≥ 3 × ULN (5 × ULN for patients with liver metastases)
  17. Administration of injectable anticoagulants during the screening period and 3 months before is prohibited. The maximum permissible daily dose of tableted anticoagulants: rivaroxaban - no more than 20 mg, apixaban - no more than 10 mg per day for patients with non-valvular atrial fibrillation and no more than 5 mg for the prevention of recurrence of deep vein thrombosis and/or PATE
  18. Conditions that limit the patient's ability to comply with the requirements of the protocol (dementia, neurological or psychiatric disorders, drug addiction, alcohol addiction, religious or personal beliefs of the patient, which may potentially limit standard therapy methods within the study, etc.)
  19. Concurrent participation in other interventional and non-interventional clinical studies less than 28 days before the IC form is signed (provided the patient has received at least one dose of experimental therapy), and previous participation in this clinical study (provided the patient has received at least one administration of RPH-051)
  20. Current continuous daily treatment with (at a dose equivalent to > 10 mg/day of methylprednisolone) (excluding inhaled steroids)
  21. Acute infectious diseases or activation of chronic infectious diseases, including those requiring intravenous injection of antibacterial drugs, less than 28 days before signing of the IC form
  22. Active or C, infection, syphilis
  23. Inability to administer the study drug intravenously
  24. Inability to perform intravenous contrast
  25. to any of the components of the study drugs specified in the protocol, or intolerance to any of the drug products for premedication
  26. Pregnancy or breastfeeding
  27. Any other significant concomitant diseases or conditions that could, in the reasonable opinion of the Investigator, adversely affect the patient's participation and well-being in the study and/or distort the evaluation of the study results
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
246 participants (estimated)

Study arms

  • Experimental
    RPH-051 + Trastuzumab + Docetaxel

    RPH-051 will be administered on Day 1 of each 21-day cycle, with a loading dose of 840 mg given as a 60-minute intravenous infusion in Cycle 1, followed by a maintenance dose of 420 mg every 3 weeks as a 30-60-minute infusion until disease progression or unacceptable toxicity Trastuzumab will be administered on Day 1 of each 21-day cycle, with a loading dose of 8 mg/kg given as a 90-minute intravenous infusion in Cycle 1, followed by a maintenance dose of 6 mg/kg every 3 weeks. If the initial loading dose is well tolerated, trastuzumab may be administered as a 30-minute infusion. Treatment continues until disease progression or unacceptable toxicity Docetaxel will be administered on Day 1 of each 21-day cycle at a dose of 75 mg/m\^2 for 6 cycles, given as a one-hour intravenous infusion

    Drug: RPH-051 · Drug: Docetaxel · Drug: Trastuzumab

  • Active comparator
    Perjeta® + Trastuzumab + Docetaxel

    Perjeta® will be administered on Day 1 of each 21-day cycle, with a loading dose of 840 mg given as a 60-minute intravenous infusion in Cycle 1, followed by a maintenance dose of 420 mg every 3 weeks as a 30-60-minute infusion until disease progression or unacceptable toxicity Trastuzumab will be administered on Day 1 of each 21-day cycle, with a loading dose of 8 mg/kg given as a 90-minute intravenous infusion in Cycle 1, followed by a maintenance dose of 6 mg/kg every 3 weeks. If the initial loading dose is well tolerated, trastuzumab may be administered as a 30-minute infusion. Treatment continues until disease progression or unacceptable toxicity Docetaxel will be administered on Day 1 of each 21-day cycle at a dose of 75 mg/m\^2 for 6 cycles, given as a one-hour intravenous infusion

    Drug: Docetaxel · Drug: Perjeta® · Drug: Trastuzumab

Interventions

  • DrugRPH-051

    RPH-051: concentrate for solution for infusion, 30 mg/mL 14 mL of the liquid concentrate is diluted with 250 mL of 0.9% sodium chloride solution. The nominal concentration of the prepared solution is 3.0 mg/mL for the loading dose and 1.6 mg/mL for the maintenance dose

  • Docetaxel: concentrate for solution for infusion, 20 mg/mL

  • Perjeta®: concentrate for solution for infusion, 30 mg/mL 14 mL of the liquid concentrate is diluted with 250 mL of 0.9% sodium chloride solution. The nominal concentration of the prepared solution is 3.0 mg/mL for the loading dose and 1.6 mg/mL for the maintenance dose

  • Trastuzumab: lyophilisate for preparation of a concentrate for solution for infusion, 440 mg or 150 mg The contents of the vial (440 mg) are dissolved in 20 mL of bacteriostatic water for injection supplied with the drug, containing 1.1% benzyl alcohol. The contents of the vial (150 mg) are dissolved in 7.2 mL of sterile water for injection

06

What researchers measure

Primary outcomes

  1. Objective response rate (%) (ORR)

    Objective response rate (%) (ORR) for a period of up to 18 weeks of therapy inclusive. ORR is the percentage of patients in a group achieving either a complete or partial tumor response to therapy. Complete Response (CR) is the disappearance of all target lesions confirmed by the computer tomography (CT) for at least 4 weeks; the short axis of any previously pathological lymph node (target or non-target) must be \< 10 mm. Partial Response (PR) is at least a 30% reduction in the sum of diameters of target lesions, maintained for at least 4 weeks compared with baseline (screening) values

    Time frame: Up to day 126

Secondary outcomes

  1. Disease control rate (DCR) (%)

    Disease control rate (DCR) (%) for a period of up to 18 weeks of therapy inclusive. DCR is the percentage of patients in a group achieving a complete or partial tumor response to therapy, or disease stabilization. Stable Disease (SD) is defined as neither a sufficient decrease in the sum of diameters of target lesions to qualify as a partial response, nor an increase in the sum of diameters that would be considered disease progression, compared with the smallest sum of diameters recorded during the observation period

    Time frame: Up to day 126

  2. Time to tumor response to therapy (TTR)

    Time to tumor response to therapy (TTR) for a period of up to 18 weeks of therapy inclusive. TTR is the time from the start of the study therapy to the first documented objective tumor response

    Time frame: Up to day 126

  3. Duration of tumor response to therapy (DOR)

    Duration of tumor response to therapy (DOR) for a period of up to 18 weeks of therapy inclusive. DOR is the time from the first documented objective tumor response to disease progression or death from any cause. Progression (PD) is defined as a ≥20% increase in the sum of diameters of target lesions compared with the smallest sum recorded during the observation period (with an absolute increase of at least 5 mm), or the appearance of one or more new lesions

    Time frame: Up to day 126

  4. Progression-free survival (PFS) expressed as PFS level (%)

    Progression-free survival (PFS) expressed as PFS level (%) for a period of up to 18 weeks of therapy inclusive

    Time frame: Up to day 126

  5. Progression-free survival (PFS) expressed as median PFS

    Progression-free survival (PFS) expressed as median PFS for a period of up to 18 weeks of therapy inclusive

    Time frame: Up to day 126

  6. Area under the pharmacokinetic curve "concentration-time" (AUC(0-504)) of pertuzumab

    Area under the pharmacokinetic curve "concentration-time" of pertuzumab after the first (single dose) administration, truncated at the point before the second administration, i.e. up to 504 hours

    Time frame: Pre-dose on Day 1 (first administration) and 1, 1.5, 2, 2.5, 4, 7, 12 hours post-dose; 24 (Day 2), 96 (Day 5), 216 (Day 10), 336 (Day 15), 504 (Day 22) hours post-dose

  7. Maximum serum concentration of pertuzumab after the first administration (Cmax)

    Maximum serum concentration of pertuzumab after the first administration (Cmax)

    Time frame: Pre-dose on Day 1 (first administration) and 1, 1.5, 2, 2.5, 4, 7, 12 hours post-dose; 24 (Day 2), 96 (Day 5), 216 (Day 10), 336 (Day 15), 504 (Day 22) hours post-dose

  8. Maximum serum concentration of pertuzumab at steady state (Cmax ss) after the 3rd administration

    Maximum serum concentration of pertuzumab at steady state (Cmax ss) after the 3rd administration

    Time frame: Pre-dose on Day 43 (+2 days, third infusion) and 1, 1.5, 2, 2.5, 4, 7, 12 hours post-dose; 24 (+72 h, Day 44 +2), 96 (+72 h, Day 47 +2), 216 (+72 h, Day 52 +2), 336 (+72 h, Day 57 +2), 504 (+72 h, Day 64 +2) hours post-dose

  9. Minimum serum concentration of pertuzumab at steady state (Cmin ss) after the 3rd administration

    Minimum serum concentration of pertuzumab at steady state (Cmin ss) after the 3rd administration

    Time frame: Pre-dose immediately before the second, third (Day 43 +2), fourth, fifth (Day 85 +2), and sixth (Day 106 +2) infusions (≤ 30 minutes before administration)

  10. Area under the pharmacokinetic curve "concentration-time" of pertuzumab at steady state (AUC tau ss)

    Area under the pharmacokinetic curve "concentration-time" of pertuzumab at steady state (AUC tau ss) after the 3rd administration

    Time frame: Pre-dose on Day 43 (+2 days, third infusion) and 1, 1.5, 2, 2.5, 4, 7, 12 hours post-dose; 24 (+72 h, Day 44 +2), 96 (+72 h, Day 47 +2), 216 (+72 h, Day 52 +2), 336 (+72 h, Day 57 +2), 504 (+72 h, Day 64 +2) hours post-dose

Other outcomes

  1. Objective response rate (%) (ORR)

    Objective response rate (%) (ORR) for a period of up to 24 weeks of therapy inclusive

    Time frame: Up to day 168

  2. Objective response rate (%) (ORR) (non-comparative evaluation in the RPH-051 group)

    Objective response rate (%) (ORR) for a period of up to 1 year of therapy inclusive (non-comparative evaluation in the RPH-051 group)

    Time frame: Up to day 365

  3. Disease control (DCR) (%)

    Disease control (DCR) (%) for a period of up to 24 weeks of therapy inclusive

    Time frame: Up to day 168

  4. Disease control (DCR) (%) (non-comparative evaluation in the RPH-051 group)

    Disease control (DCR) (%) within a period of up to 1 year of therapy inclusive (non-comparative evaluation in the RPH-051 group)

    Time frame: Up to day 365

  5. Tumor time to response to therapy (TTR)

    Tumor time to response to therapy (TTR) for a period of up to 24 weeks of therapy inclusive

    Time frame: Up to day 168

  6. Tumor time to response to therapy (TTR) (non-comparative evaluation in the RPH-051 group)

    Tumor time to response to therapy (TTR) within a period of up to 1 year of therapy inclusive (non-comparative evaluation in the RPH-051 group)

    Time frame: Up to day 365

  7. Tumor duration to response to therapy (DOR)

    Tumor duration to response to therapy (DOR) for a period of up to 24 weeks of therapy inclusive

    Time frame: Up to day 168

  8. Tumor duration to response to therapy (DOR) (non-comparative evaluation in the RPH-051 group)

    Tumor duration to response to therapy (DOR) within a period of up to 1 year of therapy inclusive (non-comparative evaluation in the RPH-051 group)

    Time frame: Up to day 365

  9. Progression-free survival (PFS) (non-comparative evaluation in the RPH-051 group)

    Progression-free survival (PFS) expressed as the rate (%) of PFS for a period of up to 24 weeks of therapy inclusive

    Time frame: Up to day 168

  10. Progression-free survival (PFS) (non-comparative evaluation in the RPH-051 group)

    Progression-free survival (PFS) expressed as the rate (%) of 1-year PFS (non-comparative evaluation in the RPH-051 group)

    Time frame: Up to day 365

  11. Progression-free survival (PFS) expressed as median PFS

    Progression-free survival (PFS) expressed as median PFS for a period of up to 24 weeks of therapy inclusive

    Time frame: Up to day 168

  12. Progression-free survival (PFS) expressed as median PFS (non-comparative evaluation in the RPH-051 group)

    Progression-free survival (PFS) expressed as median PFS for a period of up to 1 year of therapy inclusive (non-comparative evaluation in the RPH-051 group)

    Time frame: Up to day 365

  13. Overall survival (OS) (non-comparative evaluation in the RPH-051 group)

    Overall survival (OS) expressed as 1-year OS rate (non-comparative evaluation in the RPH-051 group)

    Time frame: Up to day 365

  14. Overall survival (OS) (non-comparative evaluation in the RPH-051 group)

    Overall survival (OS) expressed as median OS for a period of up to 1 year of therapy (non-comparative evaluation in the RPH-051 group)

    Time frame: Up to day 365

  15. Proportion of patients (%) with adverse drug reactions (ADRs) of any severity

    Proportion of patients (%) with ADRs of any severity

    Time frame: Days: 1 - 730 (up to 28±2 days after last administration)

  16. Proportion of patients (%) with AEs of any severity

    Proportion of patients (%) with AEs of any severity

    Time frame: Days: 1 - 730 (up to 28±2 days after last administration)

  17. Proportion of patients (%) with AEs of severity grade ≥ 3

    Proportion of patients (%) with AEs of severity grade ≥ 3

    Time frame: Days: 1 - 730 (up to 28±2 days after last administration)

  18. Proportion of patients (%) with ADRs of severity grade ≥ 3

    Proportion of patients (%) with ADRs of severity grade ≥ 3

    Time frame: Days: 1 - 730 (up to 28±2 days after last administration)

  19. Proportion of patients (%) with serious adverse events (SAEs)

    Proportion of patients (%) with SAEs

    Time frame: Days: 1 - 730 (up to 28±2 days after last administration)

  20. Proportion of patients (%) with serious adverse drug reactions (SADRs)

    Proportion of patients (%) with SADRs

    Time frame: Days: 1 - 730 (up to 28±2 days after last administration)

  21. Proportion of patients (%) who required discontinuation of treatment due to development of ADRs

    Proportion of patients (%) who required discontinuation of treatment due to development of ADRs

    Time frame: Days: 1 - 730 (up to 28±2 days after last administration)

  22. Proportion of patients (%) who developed anti-drug antibodies (ADA) to pertuzumab

    Proportion of patients (%) who developed ADA to pertuzumab

    Time frame: Pre-dose on Day 1, 43, 106 (main period) and Day 169, 190, 274, 258 (extended therapy period) (≤ 30 minutes before administration)

  23. Proportion of patients (%) who developed neutralizing antibodies (NAb) to pertuzumab

    Proportion of patients (%) who developed NAb to pertuzumab

    Time frame: Pre-dose on Day 1, 43, 106 (main period) and Day 169, 190, 274, 258 (extended therapy period) (≤ 30 minutes before administration)

  24. Area under the pharmacokinetic curve "concentration-time" (AUC(0-∞)) of pertuzumab

    Area under the pharmacokinetic curve "concentration-time" of pertuzumab after the first administration to infinity (AUC(0-∞))

    Time frame: Pre-dose on Day 1 (first administration) and 1, 1.5, 2, 2.5, 4, 7, 12 hours post-dose; 24 (Day 2), 96 (Day 5), 216 (Day 10), 336 (Day 15), 504 (Day 22) hours post-dose

  25. Time to reach the maximum concentration of pertuzumab in the blood serum after the first administration (Tmax)

    Time to reach the maximum concentration of pertuzumab in the blood serum after the first administration (Tmax)

    Time frame: Pre-dose on Day 1 (first administration) and 1, 1.5, 2, 2.5, 4, 7, 12 hours post-dose; 24 (Day 2), 96 (Day 5), 216 (Day 10), 336 (Day 15), 504 (Day 22) hours post-dose

  26. Elimination half-life of pertuzumab after the first administration (T1/2)

    Elimination half-life of pertuzumab after the first administration (T1/2)

    Time frame: Pre-dose on Day 1 (first administration) and 1, 1.5, 2, 2.5, 4, 7, 12 hours post-dose; 24 (Day 2), 96 (Day 5), 216 (Day 10), 336 (Day 15), 504 (Day 22) hours post-dose

  27. Volume of distribution of pertuzumab after the first administration (Vd)

    Volume of distribution of pertuzumab after the first administration (Vd)

    Time frame: Pre-dose on Day 1 (first administration) and 1, 1.5, 2, 2.5, 4, 7, 12 hours post-dose; 24 (Day 2), 96 (Day 5), 216 (Day 10), 336 (Day 15), 504 (Day 22) hours post-dose

  28. Elimination rate constant of pertuzumab after the first administration (Kel)

    Elimination rate constant of pertuzumab after the first administration (Kel)

    Time frame: Pre-dose on Day 1 (first administration) and 1, 1.5, 2, 2.5, 4, 7, 12 hours post-dose; 24 (Day 2), 96 (Day 5), 216 (Day 10), 336 (Day 15), 504 (Day 22) hours post-dose

  29. Area under the pharmacokinetic curve "concentration-time" of pertuzumab to infinity at steady state (AUC(0-∞) ss)

    Area under the pharmacokinetic curve "concentration-time" of pertuzumab to infinity at steady state (AUC(0-∞) ss)

    Time frame: Pre-dose on Day 43 (+2 days, third infusion) and 1, 1.5, 2, 2.5, 4, 7, 12 hours post-dose; 24 (+72 h, Day 44 +2), 96 (+72 h, Day 47 +2), 216 (+72 h, Day 52 +2), 336 (+72 h, Day 57 +2), 504 (+72 h, Day 64 +2) hours post-dose

  30. Time to reach the maximum concentration of pertuzumab at steady state (Tmax ss)

    Time to reach the maximum concentration of pertuzumab at steady state (Tmax ss)

    Time frame: Pre-dose on Day 43 (+2 days, third infusion) and 1, 1.5, 2, 2.5, 4, 7, 12 hours post-dose; 24 (+72 h, Day 44 +2), 96 (+72 h, Day 47 +2), 216 (+72 h, Day 52 +2), 336 (+72 h, Day 57 +2), 504 (+72 h, Day 64 +2) hours post-dose

  31. Elimination half-life of pertuzumab at steady state (T1/2 ss)

    Elimination half-life of pertuzumab at steady state (T1/2 ss)

    Time frame: Pre-dose on Day 43 (+2 days, third infusion) and 1, 1.5, 2, 2.5, 4, 7, 12 hours post-dose; 24 (+72 h, Day 44 +2), 96 (+72 h, Day 47 +2), 216 (+72 h, Day 52 +2), 336 (+72 h, Day 57 +2), 504 (+72 h, Day 64 +2) hours post-dose

  32. Volume of distribution of pertuzumab at steady state (Vd, ss)

    Volume of distribution of pertuzumab at steady state (Vd, ss)

    Time frame: Pre-dose on Day 43 (+2 days, third infusion) and 1, 1.5, 2, 2.5, 4, 7, 12 hours post-dose; 24 (+72 h, Day 44 +2), 96 (+72 h, Day 47 +2), 216 (+72 h, Day 52 +2), 336 (+72 h, Day 57 +2), 504 (+72 h, Day 64 +2) hours post-dose

  33. Residual concentration of pertuzumab at repeated administration (Cthrough)

    Residual concentration of pertuzumab at repeated administration (Cthrough)

    Time frame: Pre-dose on Day 43 (+2 days, third infusion) and 1, 1.5, 2, 2.5, 4, 7, 12 hours post-dose; 24 (+72 h, Day 44 +2), 96 (+72 h, Day 47 +2), 216 (+72 h, Day 52 +2), 336 (+72 h, Day 57 +2), 504 (+72 h, Day 64 +2) hours post-dose

07

Study locations

45 sites
  • Regional Budgetary Healthcare Institution "Kursk Oncology Research and Clinical Center named after G.E. Ostroverhov"
    Kursk, Kursk Oblast 305524, Russia
  • State Budgetary Healthcare Institution "Leningrad Regional Clinical Hospital" (SBHI "LOKH")
    Kuz'molovskiy, Leningradskaya Oblast' 188663, Russia
  • State Budgetary Healthcare Institution of Arkhangelsk Region "Arkhangelsk Clinical Oncology Dispensary"
    Arkhangelsk, 163045, Russia
  • Regional State Budgetary Healthcare Institution "Altai Regional Oncology Dispensary"
    Barnaul, 656045, Russia
  • Private Healthcare Institution "RZD-Medicine Clinical Hospital of Chelyabinsk"
    Chelyabinsk, 454048, Russia
  • Regional Budgetary Healthcare Institution "Ivanovo Regional Oncology Dispensary" (RBHI "IvOOD")
    Ivanovo, 153040, Russia
  • State Budgetary Healthcare Institution of Kaluga Region "Kaluga Regional Clinical Oncology Dispensary"
    Kaluga, 248007, Russia
  • State Autonomous Healthcare Institution "Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor M.Z. Sigal"
    Kazan', 420029, Russia
  • State Budgetary Healthcare Institution "Kuzbass Clinical Oncology Dispensary named after M.S. Rappoport" (SBHI "KCOD")
    Kemerovo, 650036, Russia
  • Kirov Regional State Clinical Budgetary Healthcare Institution "Center of Oncology and Medical Radiology"
    Kirov, 610045, Russia
  • Regional State Budgetary Healthcare Institution "Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I. Kryzhanovsky"
    Krasnoyarsk, 660133, Russia
  • State Budgetary Healthcare Institution of the City of Moscow "Moscow Multidisciplinary Clinical Center 'Kommunarka' of the Moscow Department of Healthcare" (SBHI "MMCC 'Kommunarka'")
    Moscow, 108814, Russia
  • Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation
    Moscow, 115478, Russia
  • Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov of the Ministry of Health of the Russian Federation (Sechenov University)
    Moscow, 119435, Russia
  • Branch of the Limited Liability Company "Hadassah Medical Ltd." (LLC Branch "Hadassah Medical")
    Moscow, 121205, Russia
  • Federal State Autonomous Institution "National Medical Research Center 'Medical and Rehabilitation Center'" of the Ministry of Health of the Russian Federation
    Moscow, 125367, Russia
  • Limited Liability Company "RESEARCH LAB"
    Moscow, 127521, Russia
  • State Budgetary Healthcare Institution of the City of Moscow "City Clinical Hospital named after S.S. Yudin" of the Moscow Department of Healthcare
    Moscow, 129090, Russia
  • Joint-Stock Company "Medsi Group of Companies" (JSC "Medsi Group of Companies")
    Moscow, 143442, Russia
  • Federal State Budgetary Institution "N.N. Petrov National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation
    Moscow, 197758, Russia
  • Private Medical Institution "Euromedservice" (PMI "Euromedservice")
    Moscow, Russia
  • State Budgetary Healthcare Institution of the City of Moscow "Moscow Clinical Scientific and Practical Center named after A.S. Loginov of the Moscow Department of Healthcare"
    Moscow, Russia
  • Limited Liability Company "Novaya Liniya"
    Nal'chik, 360003, Russia
  • State Autonomous Healthcare Institution of the Nizhny Novgorod Region "Research Institute of Clinical Oncology 'Nizhny Novgorod Regional Clinical Oncology Dispensary'"
    Nizhny Novgorod, 603081, Russia
  • Limited Liability Company Medical and Sanitary Unit "Clinician-Pretor Clinic"
    Novosibirsk, 630091, Russia
  • Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of the Russian Federation
    Obninsk, 125284, Russia
  • Federal State Budgetary Healthcare Institution "Clinical Hospital No. 8 of the Federal Medical-Biological Agency" (FSBHI CH No. 8 FMBA)
    Obninsk, 249030, Russia
  • Budgetary Healthcare Institution of Omsk Region "Clinical Oncology Dispensary"
    Omsk, 644046, Russia
  • State Budgetary Healthcare Institution of Perm Krai "Perm Krai Oncology Dispensary"
    Perm, 614066, Russia
  • State Budgetary Healthcare Institution of Stavropol Krai "Pyatigorsk Interdistrict Oncology Dispensary"
    Pyatigorsk, 357500, Russia
  • Federal State Budgetary Institution "National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation
    Rostov-on-Don, 344037, Russia
  • Joint-Stock Company "Modern Medical Technologies"
    Saint Petersburg, 190121, Russia
  • Limited Liability Company "EuroCityClinic"
    Saint Petersburg, 197022, Russia
  • Federal State Budgetary Institution "N.N. Petrov National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation
    Saint Petersburg, 197758, Russia
  • State Budgetary Healthcare Institution "St. Petersburg Clinical Scientific and Practical Center for Specialized Medical Care (Oncology) named after N.P. Napalkov"
    Saint Petersburg, 197758, Russia
  • Saint Petersburg State Budgetary Healthcare Institution "City Clinical Oncology Dispensary" (SPB SBHI CCOD)
    Saint Petersburg, 198255, Russia
  • State Healthcare Institution "Regional Clinical Oncology Dispensary" (SHI "RCOD")
    Saratov, 410053, Russia
  • Regional State Budgetary Healthcare Institution "Smolensk Regional Oncology Clinical Dispensary"
    Smolensk, 214000, Russia
  • Federal State Budgetary Educational Institution of Higher Education "Siberian State Medical University" of the Ministry of Health of the Russian Federation
    Tomsk, 634028, Russia
  • Federal State Budgetary Scientific Institution "Tomsk National Research Medical Center of the Russian Academy of Sciences" (FSBSI "Tomsk NRMC of the Russian Academy of Sciences")
    Tomsk, 634045, Russia
  • State Healthcare Institution "Tula Regional Clinical Oncology Dispensary" (SHI "TRCOD")
    Tula, 300039, Russia
  • State Autonomous Healthcare Institution "Republican Clinical Oncology Dispensary" of the Ministry of Health of the Republic of Bashkortostan
    Ufa, 450054, Russia
  • State Budgetary Healthcare Institution "Volgograd Regional Clinical Oncology Dispensary"
    Volgograd, 400138, Russia
  • State Budgetary Healthcare Institution of Yaroslavl Region "Regional Clinical Oncology Hospital"
    Yaroslavl, 150054, Russia
  • State Autonomous Healthcare Institution of Sverdlovsk Region "Sverdlovsk Regional Oncology Dispensary"
    Yekaterinburg, 620036, Russia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Oct 2025, 14 months.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 14 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 4, 2026
StartActual
Aug 9, 2024
Primary completionActual
Oct 15, 2025
CompletionEst.
May 28, 2027
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07386938
Lead sponsor
R-Pharm
Responsible party
Sponsor
First posted
Feb 4, 2026
Start date
Aug 9, 2024
Primary completion
Oct 15, 2025
Completion
May 28, 2027 (estimated)
Last update
Jul 14, 2026

Study contacts

Mikhail Samsonov
study director · R-Pharm

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion